Cardinal Health, Inc. (CAH) has been drawing significant attention in the biotech market for its robust performance. Driven by steady healthcare momentum, the company's stock hit an all-time high at
166.33 USD. Moreover, it aims to bank on the
growth of its specialty drugs unit to further enhance profitability. Analyst Jim Cramer emphasized the company's impressive performance and leadership. Estimates show that CAH might be
underestimated by 33%, considering its intrinsic value. Amid Individual Retirement Account (IRA) tailwinds and strong healthcare sector strength, the company targets double-digit EPS growth. Cardinal Health envisages updated long-term value creation plans, confirming promising investor days. Meanwhile, impressive Q1 results showed the company surpassing profit expectations, regardless of missed revenue targets. News on CAH's developments in R&D is also noteworthy, with the release of a report on the cell and gene therapy industry and the launch of a device for critical vital signs monitoring. However, potential risks loom as the company experiences tariff headwinds and layoffs. Multiple deals have been made to expand the company's businesses, helping raise its earnings outlook. Many upgrades and price target advancements point towards a bullish future for CAH in the upcoming time. However, long term growth plans remain to be tested.
Cardinal Health CAH News Analytics from Fri, 01 Nov 2024 07:00:00 GMT to Sat, 28 Jun 2025 05:26:09 GMT -
Rating 8
- Innovation 4
- Information 7
- Rumor -5
